Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?
- PMID: 35694414
- PMCID: PMC8982531
- DOI: 10.1093/pcmedi/pbaa021
Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?
Abstract
Poor drug compliance and drug-resistant Mycobacterium tuberculosis are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the N-acetyl transferase-2-isoniazid (NAT2-INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.
Keywords: India; N-acetyl transferase-2; isoniazid; personalized medicine; tuberculosis.
© The Author(s) 2020. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University.
Similar articles
-
Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India.Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):443-447. doi: 10.1007/s13318-022-00764-x. Epub 2022 Mar 28. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35349098
-
A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.Indian J Tuberc. 2020 Jul;67(3):407-410. doi: 10.1016/j.ijtb.2020.01.005. Epub 2020 Jan 20. Indian J Tuberc. 2020. PMID: 32825881
-
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.Clin Ther. 2020 Nov;42(11):e220-e241. doi: 10.1016/j.clinthera.2020.09.009. Epub 2020 Oct 5. Clin Ther. 2020. PMID: 33032843
-
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.Int J Tuberc Lung Dis. 2016 Sep;20(9):1236-41. doi: 10.5588/ijtld.16.0048. Int J Tuberc Lung Dis. 2016. PMID: 27510252
-
Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.Curr Drug Metab. 2017;18(11):1030-1039. doi: 10.2174/1389200218666171031121905. Curr Drug Metab. 2017. PMID: 29086682 Review.
Cited by
-
Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.Pharmgenomics Pers Med. 2022 Jun 4;15:561-571. doi: 10.2147/PGPM.S363058. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35693129 Free PMC article. Review.
References
-
- WHO Global TB Report 2019. https://www.who.int/tb/publications/global_report/en/ (accessed May 23, 2020).
-
- Central TB Division. India TB Report 2019. https://tbcindia.gov.in/WriteReadData/India%20TB%20Report%202019.pdf (accessed May 23, 2020).
LinkOut - more resources
Full Text Sources